Black Diamond provides 2024 milestones: Phase 2 data for BDTX-1535 in NSCLC expected Q3; cash into Q2 2025

Black Diamond Therapeutics, Inc.

FDA feedback enables Phase 2 first-line cohort for BDTX-1535 in non-classical EGFR mutant NSCLC; Fast Track granted for second-line C797S.
Phase 2 results for second/third-line EGFR mutant NSCLC expected Q3 2024; Phase 1 and window-of-opportunity GBM data expected Q2 2024.
Phase 1 results for BDTX-4933 in KRAS mutant NSCLC expected Q4 2024.
Existing cash, cash equivalents and investments expected to fund operations into Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.